爵士制药:Ziihera联合化疗额外预设总生存期中期分析预计2026年中进行

美股速递
Jan 07

爵士制药(Jazz Pharmaceuticals PLC)近日更新其研发管线进展,针对Ziihera与化疗联合疗法的额外预设总生存期(OS)中期分析时间表作出调整。根据最新规划,该项关键数据分析目前预计将于2026年中期完成。

此次中期分析旨在评估Ziihera结合标准化疗在特定患者群体中的长期疗效与安全性表现。作为药物获批路径中的重要节点,分析结果将为后续注册申请及临床用药策略提供关键依据。

公司强调,该时间安排基于现有临床进展与监管沟通结果,未来可能根据实际研究进展动态调整。业界关注此次分析是否能为Ziihera的全球上市布局注入新动能。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10